Vaxcyte Inc

NASDAQ:PCVXUnited States

Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Company’s next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.

Contact Information

Headquarters

825 INDUSTRIAL ROAD, STE. 300SAN CARLOS, CA, United States 94070

Phone

650-837-0111

Fax

302-655-5049

Executives

Independent Chairman of the Board

Carlos Paya

President, Chief Financial Officer

Andrew Guggenhime

Chief Executive Officer, Co-Founder, Director

Grant Pickering

Executive Vice President, Chief Operating Officer

James Wassil

Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary

Mikhail Eydelman